Gary Herbert Lyman, MD

Adjunct Professor in the Department of Medicine
Campus mail 2424 Erwin Road, Suite 205, Durham, NC 27705
Phone (919) 681-1736
Email address gary.lyman@duke.edu

Dr. Gary Lyman is Professor of Medicine in the Division of Medical Oncology, Department of Internal Medicine at Duke University School of Medicine and the Duke Cancer Institute. He serves as Director of the Comparative Effectiveness and Outcomes Research Program in Oncology. Dr Lyman is also Senior Fellow in the Duke Center for Clinical Health Policy Research. He is a nationally and internationally recognized authority on comparative effectiveness and health services and outcomes research. Lyman research is funded by the National Cancer Institute, the National Heart Lung and Blood Institute, the American Society of Clinical Oncology along with industry grants related to supportive cancer care. Dr Lyman has published some 400 research articles in in the professional medical literature. Direct funding from all sources supports an annual Comparative Effectiveness and Outcomes Research budget of over $5 million.

Dr Lyman’s research interests include:
Personalized Medicine and Cancer Supportive Care: In addition to the conduct of randomized controlled trials of new cancer diagnostic, prognostic, treatment and supportive care approaches, Dr Lyman’s research interests include the personalized management of early-stage breast cancer and supportive care of patients receiving cancer chemotherapy, most notably those at risk for febrile neutropenia and venous thromboembolism. Based on clinical trial results, Dr Lyman is actively involved in the development and validation of clinical risk models for patient selection and targeted intervention and preventive strategies. Dr Lyman is co-PI on an NCI on comparative effectiveness of cancer pharmacogenomics grant to discover and validate new genomic tools for guiding more personalized cancer treatments and on an NHLBI trial of thromboprophylaxis in high risk ambulatory patients receiving cancer chemotherapy.

Evidence synthesis, clinical practice guidelines and health policy: Dr Lyman conducts systematic reviews and meta-analyses of major clinical issues in support of clinical practice guidelines. Dr Lyman chairs several guidelines for the American Society of Clinical Oncology including those on antiemetics, venous thromboembolism, sentinel node biopsy in patients with breast cancer and cutaneous melanoma and on weight based dosing of chemotherapy. Dr Lyman also conducts analyses of large population studies of clinical outcomes associated with of current cancer patient management in a real world setting with a particular focus on cancer management in the elderly patient with cancer. Dr Lyman leads several decision simulation studies for improved clinical decision making and cost-effectiveness analysis of new and novel therapies based on results of clinical trials, systematic reviews and population studies. He serves as an advisor on new oncologic agents to the US FDA. Dr Lyman also serves as Editor-in-Chief of Cancer Investigation and on the editorial boards of several prestigious research journals.

Education and Training

  • Research Fellow, Medicine, Dana-Farber Cancer Institute, 1981 - 1982
  • Medical Oncology Clinical Fellowship, Medicine, Roswell Park Cancer Institute, 1974 - 1976
  • Intern and Junior Assistant Resident, Medicine, University of North Carolina - Chapel Hill, 1972 - 1974
  • M.D., State University of New York - Buffalo, 1972

Publications

Lyman, G. H., M. Reiner, P. K. Morrow, and J. Crawford. “The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy.” Ann Oncol 26, no. 7 (July 2015): 1452–58. https://doi.org/10.1093/annonc/mdv174.

PMID
25851633
Full Text

Lyman, Gary H., Kari Bohlke, Alok A. Khorana, Nicole M. Kuderer, Agnes Y. Lee, Juan Ignacio Arcelus, Edward P. Balaban, et al. “Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014.” J Clin Oncol 33, no. 6 (February 20, 2015): 654–56. https://doi.org/10.1200/JCO.2014.59.7351.

PMID
25605844
Full Text

Dinan, Michaela A., Bradford R. Hirsch, and Gary H. Lyman. “Management of chemotherapy-induced neutropenia: measuring quality, cost, and value.” J Natl Compr Canc Netw 13, no. 1 (January 2015): e1–7. https://doi.org/10.6004/jnccn.2015.0014.

PMID
25583775
Full Text

Culakova, Eva, Marek S. Poniewierski, Debra A. Wolff, David C. Dale, Jeffrey Crawford, and Gary H. Lyman. “The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study.” Springerplus 4 (2015): 396. https://doi.org/10.1186/s40064-015-1165-6.

PMID
26251780
Full Text

Fust, Kelly, Xiaoyan Li, Michael Maschio, Richard Barron, Milton C. Weinstein, Anju Parthan, Marjan Walli-Attaei, David B. Chandler, and Gary H. Lyman. “Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.” Gynecol Oncol 133, no. 3 (June 2014): 446–53. https://doi.org/10.1016/j.ygyno.2014.03.014.

PMID
24657302
Full Text

Weycker, Derek, Richard Barron, Alex Kartashov, Jason Legg, and Gary H. Lyman. “Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings.” J Oncol Pharm Pract 20, no. 3 (June 2014): 190–98. https://doi.org/10.1177/1078155213492450.

PMID
23824496
Full Text

Hoang, J. K., K. R. Choudhury, J. D. Eastwood, R. M. Esclamado, G. H. Lyman, T. M. Shattuck, and X. V. Nguyen. “An exponential growth in incidence of thyroid cancer: trends and impact of CT imaging.” Ajnr Am J Neuroradiol 35, no. 4 (April 2014): 778–83. https://doi.org/10.3174/ajnr.A3743.

PMID
24113469
Full Text

Kuderer, N. M., and G. H. Lyman. “Guidelines for treatment and prevention of venous thromboembolism among patients with cancer.” Thrombosis Research 133, no. SUPPL. 2 (2014): S122–27. https://doi.org/10.1016/S0049-3848(14)50021-7.

Full Text

Buchholz, T. A., M. R. Somerfield, J. J. Griggs, S. El-Eid, M. E. H. Hammond, G. H. Lyman, G. Mason, and L. A. Newman. “Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 32, no. 14 (2014): 1502–6. https://doi.org/10.1200/JCO.2014.55.1572.

Full Text

Pages